Zymeworks Inc. (NYSE:ZYME) Director Acquires $992,533.75 in Stock

Posted by Anthony Bellafiore on Jan 18th, 2025

Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc bought 74,125 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were acquired at an average price of $13.39 per share, with a total value of $992,533.75. Following the transaction, the director now directly owns 15,485,203 shares of the company’s stock, valued at $207,346,868.17. This represents a 0.48 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

On Wednesday, January 15th, Ecor1 Capital, Llc purchased 39,029 shares of Zymeworks stock. The stock was acquired at an average cost of $14.01 per share, for a total transaction of $546,796.29.
On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were bought at an average price of $13.13 per share, for a total transaction of $2,679,806.74.
On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The shares were bought at an average price of $14.07 per share, with a total value of $295,765.47.
On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The stock was bought at an average price of $14.78 per share, for a total transaction of $2,333,466.40.
On Monday, December 30th, Ecor1 Capital, Llc acquired 58,988 shares of Zymeworks stock. The shares were bought at an average cost of $14.47 per share, with a total value of $853,556.36.
On Tuesday, December 24th, Ecor1 Capital, Llc bought 11,958 shares of Zymeworks stock. The stock was purchased at an average price of $14.12 per share, for a total transaction of $168,846.96.
On Thursday, December 26th, Ecor1 Capital, Llc acquired 16,692 shares of Zymeworks stock. The stock was purchased at an average cost of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Trading Down 0.8 %

ZYME stock opened at $13.88 on Friday. The stock has a market cap of $956.03 million, a PE ratio of -9.25 and a beta of 1.10. Zymeworks Inc. has a 12 month low of $7.97 and a 12 month high of $17.70. The company has a 50-day moving average price of $14.30 and a 200 day moving average price of $12.61.

Zymeworks (NYSE:ZYME – Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The business had revenue of $16.00 million during the quarter, compared to analyst estimates of $17.90 million. During the same quarter in the previous year, the business earned ($0.41) earnings per share. The company’s revenue for the quarter was down 3.1% compared to the same quarter last year. Sell-side analysts forecast that Zymeworks Inc. will post -1.39 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. HC Wainwright reissued a “neutral” rating and issued a $12.00 target price on shares of Zymeworks in a report on Friday, November 22nd. Leerink Partnrs upgraded shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 7th. Citigroup increased their price target on shares of Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a report on Monday, November 4th. Leerink Partners upgraded Zymeworks from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $10.00 to $25.00 in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective on the stock in a research report on Monday, December 16th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Zymeworks presently has a consensus rating of “Moderate Buy” and an average target price of $19.17.

Check Out Our Latest Analysis on ZYME

Hedge Funds Weigh In On Zymeworks

Several hedge funds have recently bought and sold shares of the business. FMR LLC lifted its position in shares of Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after purchasing an additional 1,525 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Zymeworks in the 3rd quarter worth about $47,000. Quest Partners LLC increased its stake in Zymeworks by 8,049.6% in the 2nd quarter. Quest Partners LLC now owns 9,209 shares of the company’s stock worth $78,000 after buying an additional 9,096 shares during the period. nVerses Capital LLC bought a new stake in Zymeworks during the 3rd quarter valued at about $79,000. Finally, MQS Management LLC purchased a new stake in Zymeworks in the 2nd quarter valued at about $92,000. Institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.